Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus

A. Kanerva, K. R. Zinn, Kah-Whye Peng, T. Ranki, L. Kangasniemi, T. R. Chaudhuri, R. A. Desmond, M. Wang, K. Takayama, T. Hakkarainen, H. Alfthan, U. H. Stenman, D. T. Curiel, A. Hemminki

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

In clinical trials with cancer patients, the safety of conditionally replicating adenoviruses (CRAds) has been good. However, marginal data are available on the persistence or antitumor efficacy of these agents. The oncolytic potency of CRAds is determined by their capacity for entering target cells. Consequently, we constructed a retargeted CRAd featuring a secreted marker protein, soluble human carcinoembryogenic antigen (hCEA), which can be measured in growth medium or plasma. We found that virus replication closely correlated with hCEA secretion both in vitro and in vivo. Further, antitumor efficacy and the persistence of the virus could be deduced from plasma hCEA levels. Finally, using in vivo bioluminescence imaging, we were able to detect effective tumor cell killing by the virus, which led to enhanced therapeutic efficacy.

Original languageEnglish (US)
Pages (from-to)87-94
Number of pages8
JournalGene Therapy
Volume12
Issue number1
DOIs
StatePublished - Jan 2005

Fingerprint

Adenoviridae
Antigens
Viruses
Neoplasms
Patient Safety
Virus Replication
Antineoplastic Agents
Clinical Trials
Growth
Proteins
Therapeutics

Keywords

  • Adenovirus
  • Imaging
  • Ovarian neoplasms
  • Virus replication

ASJC Scopus subject areas

  • Genetics

Cite this

Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus. / Kanerva, A.; Zinn, K. R.; Peng, Kah-Whye; Ranki, T.; Kangasniemi, L.; Chaudhuri, T. R.; Desmond, R. A.; Wang, M.; Takayama, K.; Hakkarainen, T.; Alfthan, H.; Stenman, U. H.; Curiel, D. T.; Hemminki, A.

In: Gene Therapy, Vol. 12, No. 1, 01.2005, p. 87-94.

Research output: Contribution to journalArticle

Kanerva, A, Zinn, KR, Peng, K-W, Ranki, T, Kangasniemi, L, Chaudhuri, TR, Desmond, RA, Wang, M, Takayama, K, Hakkarainen, T, Alfthan, H, Stenman, UH, Curiel, DT & Hemminki, A 2005, 'Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus', Gene Therapy, vol. 12, no. 1, pp. 87-94. https://doi.org/10.1038/sj.gt.3302387
Kanerva, A. ; Zinn, K. R. ; Peng, Kah-Whye ; Ranki, T. ; Kangasniemi, L. ; Chaudhuri, T. R. ; Desmond, R. A. ; Wang, M. ; Takayama, K. ; Hakkarainen, T. ; Alfthan, H. ; Stenman, U. H. ; Curiel, D. T. ; Hemminki, A. / Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus. In: Gene Therapy. 2005 ; Vol. 12, No. 1. pp. 87-94.
@article{2f2ee19779244585b1fa661c62cf8a7b,
title = "Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus",
abstract = "In clinical trials with cancer patients, the safety of conditionally replicating adenoviruses (CRAds) has been good. However, marginal data are available on the persistence or antitumor efficacy of these agents. The oncolytic potency of CRAds is determined by their capacity for entering target cells. Consequently, we constructed a retargeted CRAd featuring a secreted marker protein, soluble human carcinoembryogenic antigen (hCEA), which can be measured in growth medium or plasma. We found that virus replication closely correlated with hCEA secretion both in vitro and in vivo. Further, antitumor efficacy and the persistence of the virus could be deduced from plasma hCEA levels. Finally, using in vivo bioluminescence imaging, we were able to detect effective tumor cell killing by the virus, which led to enhanced therapeutic efficacy.",
keywords = "Adenovirus, Imaging, Ovarian neoplasms, Virus replication",
author = "A. Kanerva and Zinn, {K. R.} and Kah-Whye Peng and T. Ranki and L. Kangasniemi and Chaudhuri, {T. R.} and Desmond, {R. A.} and M. Wang and K. Takayama and T. Hakkarainen and H. Alfthan and Stenman, {U. H.} and Curiel, {D. T.} and A. Hemminki",
year = "2005",
month = "1",
doi = "10.1038/sj.gt.3302387",
language = "English (US)",
volume = "12",
pages = "87--94",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus

AU - Kanerva, A.

AU - Zinn, K. R.

AU - Peng, Kah-Whye

AU - Ranki, T.

AU - Kangasniemi, L.

AU - Chaudhuri, T. R.

AU - Desmond, R. A.

AU - Wang, M.

AU - Takayama, K.

AU - Hakkarainen, T.

AU - Alfthan, H.

AU - Stenman, U. H.

AU - Curiel, D. T.

AU - Hemminki, A.

PY - 2005/1

Y1 - 2005/1

N2 - In clinical trials with cancer patients, the safety of conditionally replicating adenoviruses (CRAds) has been good. However, marginal data are available on the persistence or antitumor efficacy of these agents. The oncolytic potency of CRAds is determined by their capacity for entering target cells. Consequently, we constructed a retargeted CRAd featuring a secreted marker protein, soluble human carcinoembryogenic antigen (hCEA), which can be measured in growth medium or plasma. We found that virus replication closely correlated with hCEA secretion both in vitro and in vivo. Further, antitumor efficacy and the persistence of the virus could be deduced from plasma hCEA levels. Finally, using in vivo bioluminescence imaging, we were able to detect effective tumor cell killing by the virus, which led to enhanced therapeutic efficacy.

AB - In clinical trials with cancer patients, the safety of conditionally replicating adenoviruses (CRAds) has been good. However, marginal data are available on the persistence or antitumor efficacy of these agents. The oncolytic potency of CRAds is determined by their capacity for entering target cells. Consequently, we constructed a retargeted CRAd featuring a secreted marker protein, soluble human carcinoembryogenic antigen (hCEA), which can be measured in growth medium or plasma. We found that virus replication closely correlated with hCEA secretion both in vitro and in vivo. Further, antitumor efficacy and the persistence of the virus could be deduced from plasma hCEA levels. Finally, using in vivo bioluminescence imaging, we were able to detect effective tumor cell killing by the virus, which led to enhanced therapeutic efficacy.

KW - Adenovirus

KW - Imaging

KW - Ovarian neoplasms

KW - Virus replication

UR - http://www.scopus.com/inward/record.url?scp=19944430000&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944430000&partnerID=8YFLogxK

U2 - 10.1038/sj.gt.3302387

DO - 10.1038/sj.gt.3302387

M3 - Article

C2 - 15385953

AN - SCOPUS:19944430000

VL - 12

SP - 87

EP - 94

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 1

ER -